New frontiers for treatment of metabolic diseases

Mediators of Inflammation

Volumn 2018, Issue , 2018, Pages

  Belizário, José E ^a   Faintuch, Joel ^a   Garay Malpartida, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SMALL MOLECULE TRANSPORT AGENT;

DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HOST MICROBE INTERACTION; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; METABOLIC DISORDER; METABOLISM; MITOCHONDRION; NONHUMAN; NUCLEAR REPROGRAMMING; NUTRIENT; PHYSIOLOGICAL PROCESS; REVIEW; SYMBIOSIS; ANIMAL; MACROPHAGE; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HUMANS; MACROPHAGES; METABOLIC DISEASES;

EID: 85059795291     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2018/2037838     Document Type: Review

References (98)

1. F. Bäckhed, C. M. Fraser, Y. Ringel et al., “Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications,” Cell Host & Microbe, vol. 12, no. 5, pp. 611-622, 2012.
2. J. E. Belizario and M. Napolitano, “Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches,” Frontiers in Microbiology, vol. 6, p. 1050, 2015.
3. R. Sender, S. Fuchs, and R. Milo, “Revised estimates for the number of human and bacteria cells in the body,” PLoS Biology, vol. 14, no. 8, article e1002533, 2016.
4. J. Qin, R. Li, J. Raes et al., “A human gut microbial gene catalogue established by metagenomic sequencing,” Nature, vol. 464, no. 7285, pp. 59-65, 2010.
5. J. Li, H. Jia, X. Cai et al., “An integrated catalog of reference genes in the human gut microbiome,” Nature Biotechnology, vol. 32, no. 8, pp. 834-841, 2014.
6. J. Lloyd-Price, G. Abu-Ali, and C. Huttenhower, “The healthy human microbiome,” Genome Medicine, vol. 8, no. 1, p. 51, 2016.
7. J. Lloyd-Price, A. Mahurkar, G. Rahnavard et al., “Strains, functions and dynamics in the expanded Human Microbiome Project,” Nature, vol. 550, no. 7674, pp. 61-66, 2017.
8. D. H. Parks, C. Rinke, M. Chuvochina et al., “Recovery of nearly 8,000 metagenome-assembled genomes substantially expands the tree of life,” Nature Microbiology, vol. 2, no. 11, pp. 1533-1542, 2017.
9. M. Arumugam, J. Raes, E. Pelletier et al., “Enterotypes of the human gut microbiome,” Nature, vol. 473, no. 7346, pp. 174-180, 2011.
10. O. Koren, D. Knights, A. Gonzalez et al., “A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets,” PLoS Computational Biology, vol. 9, no. 1, article e1002863, 2013.
11. E. Le Chatelier, T. Nielsen, J. Qin et al., “Richness of human gut microbiome correlates with metabolic markers,” Nature, vol. 500, no. 7464, pp. 541-546, 2013.
12. A. H. Moeller, Y. Li, E. Mpoudi Ngole et al., “Rapid changes in the gut microbiome during human evolution,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 46, pp. 16431-16435, 2014.
13. V. Tremaroli and F. Bäckhed, “Functional interactions between the gut microbiota and host metabolism,” Nature, vol. 489, no. 7415, pp. 242-249, 2012.
14. I. Rowland, G. Gibson, A. Heinken et al., “Gut microbiota functions: metabolism of nutrients and other food components,” European Journal of Nutrition, vol. 57, no. 1, pp. 1-24, 2018.
15. K. Meijer, P. de Vos, and M. G. Priebe, “Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 6, pp. 715-721, 2010.
16. F. J. Gonzalez, C. Jiang, C. Xie, and A. D. Patterson, “Intestinal farnesoid X receptor signaling modulates metabolic disease,” Digestive Diseases, vol. 35, no. 3, pp. 178-184, 2017.
17. J. M. Ridlon, D. J. Kang, P. B. Hylemon, and J. S. Bajaj, “Bile acids and the gut microbiome,” Current Opinion in Gastroenterology, vol. 30, no. 3, pp. 332-338, 2014.
18. S. M. Collins, M. Surette, and P. Bercik, “The interplay between the intestinal microbiota and the brain,” Nature Reviews Microbiology, vol. 10, no. 11, pp. 735-742, 2012.
19. W. R. Wikoff, A. T. Anfora, J. Liu et al., “Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3698-3703, 2009.
20. N. Pornputtapong, I. Nookaew, and J. Nielsen, “Human metabolic atlas: an online resource for human metabolism,” Database, vol. 2015, article bav068, 2015.
21. S. Abubucker, N. Segata, J. Goll et al., “Metabolic reconstruction for metagenomic data and its application to the human microbiome,” PLoS Computational Biology, vol. 8, no. 6, article e1002358, 2012.
22. Y. Qin and P. A. Wade, “Crosstalk between the microbiome and epigenome: messages from bugs,” Journal of Biochemistry, vol. 163, no. 2, pp. 105-112, 2018.
23. M. B. Miller and B. L. Bassler, “Quorum sensing in bacteria,” Annual Review of Microbiology, vol. 55, no. 1, pp. 165-199, 2001.
24. M. J. Ostaff, E. F. Stange, and J. Wehkamp, “Antimicrobial peptides and gut microbiota in homeostasis and pathology,” EMBO Molecular Medicine, vol. 5, no. 10, pp. 1465-1483, 2013.
25. G. Reid, J. A. Younes, H. C. Van der Mei, G. B. Gloor, R. Knight, and H. J. Busscher, “Microbiota restoration: natural and supplemented recovery of human microbial communities,” Nature Reviews Microbiology, vol. 9, no. 1, pp. 27-38, 2011.
26. D. J. Palmer, J. Metcalfe, and S. L. Prescott, “Preventing disease in the 21st century: the importance of maternal and early infant diet and nutrition,” Journal of Allergy and Clinical Immunology, vol. 130, no. 3, pp. 733-734, 2012.
27. C. R. Webb, I. Koboziev, K. L. Furr, and M. B. Grisham, “Protective and pro-inflammatory roles of intestinal bacteria,” Pathophysiology, vol. 23, no. 2, pp. 67-80, 2016.
28. M. X. Byndloss, E. E. Olsan, F. Rivera-Chávez et al., “Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobac-teriaceae expansion,” Science, vol. 357, no. 6351, pp. 570-575, 2017.
29. J. C. Clemente, L. K. Ursell, L. W. Parfrey, and R. Knight, “The impact of the gut microbiota on human health: an integrative view,” Cell, vol. 148, no. 6, pp. 1258-1270, 2012.
30. E. M. Brown, M. Sadarangani, and B. B. Finlay, “The role of the immune system in governing host-microbe interactions in the intestine,” Nature Immunology, vol. 14, no. 7, pp. 660-667, 2013.
31. C. A. Thaiss, N. Zmora, M. Levy, and E. Elinav, “The microbiome and innate immunity,” Nature, vol. 535, no. 7610, pp. 65-74, 2016.
32. A. Swidsinski, V. Loening-Baucke, H. Lochs, and L. P. Hale, “Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice,” World Journal of Gastroenterology, vol. 11, no. 8, pp. 1131-1140, 2005.
33. F. J. Verdam, S. Fuentes, C. de Jonge et al., “Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,” Obesity, vol. 21, no. 12, pp. E607-E615, 2013.
34. A. Everard, C. Belzer, L. Geurts et al., “Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 22, pp. 9066-9071, 2013.
35. U. Roy, E. J. C. Gálvez, A. Iljazovic et al., “Distinct microbial communities trigger colitis development upon intestinal barrier damage via innate or adaptive immune cells,” Cell Reports, vol. 21, no. 4, pp. 994-1008, 2017.
36. J. L. Round and S. K. Mazmanian, “The gut microbiota shapes intestinal immune responses during health and disease,” Nature Reviews Immunology, vol. 9, no. 5, pp. 313-323, 2009.
37. A. J. McDermott and G. B. Huffnagle, “The microbiome and regulation of mucosal immunity,” Immunology, vol. 142, no. 1, pp. 24-31, 2014.
38. L. V. Hooper, D. R. Littman, and A. J. Macpherson, “Interactions between the microbiota and the immune system,” Science, vol. 336, no. 6086, pp. 1268-1273, 2012.
39. K. Honda and D. R. Littman, “The microbiota in adaptive immune homeostasis and disease,” Nature, vol. 535, no. 7610, pp. 75-84, 2016.
40. A. Fuchs and M. Colonna, “Natural killer (NK) and NK-like cells at mucosal epithelia: mediators of anti-microbial defense and maintenance of tissue integrity,” European Journal of Microbiology and Immunology, vol. 1, no. 4, pp. 257-266, 2011.
41. H. Kono and K. L. Rock, “How dying cells alert the immune system to danger,” Nature Reviews Immunology, vol. 8, no. 4, pp. 279-289, 2008.
42. B. Sangiuliano, N. M. Pérez, D. F. Moreira, and J. E. Belizário, “Cell death-associated molecular-pattern molecules: inflammatory signaling and control,” Mediators of Inflammation, vol. 2014, Article ID 821043, 14 pages, 2014.
43. V. A. K. Rathinam and K. A. Fitzgerald, “Inflammasome complexes: emerging mechanisms and effector functions,” Cell, vol. 165, no. 4, pp. 792-800, 2016.
44. M. Mamantopoulos, F. Ronchi, F. van Hauwermeiren et al., “Nlrp6- and ASC-dependent inflammasomes do not shape the commensal gut microbiota composition,” Immunity, vol. 47, no. 2, pp. 339-348.e4, 2017.
45. C. L. Maynard, C. O. Elson, R. D. Hatton, and C. T. Weaver, “Reciprocal interactions of the intestinal microbiota and immune system,” Nature, vol. 489, no. 7415, pp. 231-241, 2012.
46. F. R. C. Costa, M. C. S. Françozo, G. G. de Oliveira et al., “Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset,” Journal of Experimental Medicine, vol. 213, no. 7, pp. 1223-1239, 2016.
47. D. Laukens, B. M. Brinkman, J. Raes, M. De Vos, and P. Vandenabeele, “Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design,” FEMS Microbiology Review, vol. 40, no. 1, pp. 117-132, 2016.
48. J. V. Fritz, M. S. Desai, P. Shah, J. G. Schneider, and P. Wilmes, “From meta-omics to causality: experimental models for human microbiome research,” Microbiome, vol. 1, no. 1, p. 14, 2013.
49. R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Microbial ecology: human gut microbes associated with obesity,” Nature, vol. 444, no. 7122, pp. 1022-1023, 2006.
50. R. E. Ley, M. Hamady, C. Lozupone et al., “Evolution of mammals and their gut microbes,” Science, vol. 320, no. 5883, pp. 1647-1651, 2008.
51. E. L. Mills, B. Kelly, and L. A. J. O'Neill, “Mitochondria are the powerhouses of immunity,” Nature Immunology, vol. 18, no. 5, pp. 488-498, 2017.
52. K. Ganeshan and A. Chawla, “Metabolic regulation of immune responses,” Annual Review of Immunology, vol. 32, no. 1, pp. 609-634, 2014.
53. L. A. J. O'Neill, R. J. Kishton, and J. Rathmell, “A guide to immunometabolism for immunologists,” Nature Reviews Immunology, vol. 16, no. 9, pp. 553-565, 2016.
54. P. Newsholme, R. Curi, S. Gordon, and E. A. Newsholme, “Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages,” Biochemical Journal, vol. 239, no. 1, pp. 121-125, 1986.
55. C. Murphy and P. Newsholme, “Importance of glutamine metabolism in murine macrophages and human monocytes to L-arginine biosynthesis and rates of nitrite or urea production,” Clinical Science, vol. 95, no. 4, pp. 397-407, 1998.
56. O. Warburg, K. Gawehn, and A. W. Geissler, “Metabolism of leukocytes,” Zeitschrift für Naturforschung B, vol. 13B, pp. 515-516, 1958.
57. A. Sica and A. Mantovani, “Macrophage plasticity and polarization: in vivo veritas,” The Journal of Clinical Investigation, vol. 122, no. 3, pp. 787-795, 2012.
58. J. Jantsch, D. Chakravortty, N. Turza et al., “Hypoxia and hypoxia-inducible factor-1α modulate lipopolysaccharide-induced dendritic cell activation and function,” The Journal of Immunology, vol. 180, no. 7, pp. 4697-4705, 2008.
59. E. Lachmandas, L. Boutens, J. M. Ratter et al., “Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes,” Nature Microbiology, vol. 2, no. 3, article 16246, 2017.
60. L. A. J. O'Neill and E. J. Pearce, “Immunometabolism governs dendritic cell and macrophage function,” Journal of Experimental Medicine, vol. 213, no. 1, pp. 15-23, 2016.
61. V. Infantino, P. Convertini, L. Cucci et al., “The mitochondrial citrate carrier: a new player in inflammation,” Biochemical Journal, vol. 438, no. 3, pp. 433-436, 2011.
62. R. Curi, R. de Siqueira Mendes, L. A. de Campos Crispin, G. D. Norata, S. C. Sampaio, and P. Newsholme, “A past and present overview of macrophage metabolism and functional outcomes,” Clinical Science, vol. 131, no. 12, pp. 1329-1342, 2017.
63. G. M. Tannahill, A. M. Curtis, J. Adamik et al., “Succinate is an inflammatory signal that induces IL-1β through HIF-1α,” Nature, vol. 496, no. 7444, pp. 238-242, 2013.
64. E. M. Palsson-McDermott, A. M. Curtis, G. Goel et al., “Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the Warburg effect in LPS-activated macrophages,” Cell Metabolism, vol. 21, no. 1, pp. 65-80, 2015.
65. V. Lampropoulou, A. Sergushichev, M. Bambouskova et al., “Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation,” Cell Metabolism, vol. 24, no. 1, pp. 158-166, 2016.
66. B. Németh, J. Doczi, D. Csete et al., “Abolition of mitochondrial substrate-level phosphorylation by itaconic acid produced by LPS-induced Irg1 expression in cells of murine macrophage lineage,” The FASEB Journal, vol. 30, no. 1, pp. 286-300, 2016.
67. T. Cordes, M. Wallace, A. Michelucci et al., “Immunorespon-sive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels,” Journal of Biological Chemistry, vol. 291, no. 27, pp. 14274-14284, 2016.
68. A. Michelucci, T. Cordes, J. Ghelfi et al., “Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 19, pp. 7820-7825, 2013.
69. D. Zeevi, T. Korem, N. Zmora et al., “Personalized nutrition by prediction of glycemic responses,” Cell, vol. 163, no. 5, pp. 1079-1094, 2015.
70. I. T. W. Harley and C. L. Karp, “Obesity and the gut microbiome: striving for causality,” Molecular Metabolism, vol. 1, no. 1-2, pp. 21-31, 2012.
71. P. D. Cani, A. M. Neyrinck, F. Fava et al., “Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia,” Diabetologia, vol. 50, no. 11, pp. 2374-2383, 2007.
72. R. S. Kootte, A. Vrieze, F. Holleman et al., “The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus,” Diabetes, Obesity and Metabolism, vol. 14, no. 2, pp. 112-120, 2012.
73. T. Arora and F. Backhed, “The gut microbiota and metabolic disease: current understanding and future perspectives,” Journal of Internal Medicine, vol. 280, no. 4, pp. 339-349, 2016.
74. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” Nature, vol. 444, no. 7122, pp. 1027-1031, 2006.
75. P. J. Turnbaugh, M. Hamady, T. Yatsunenko et al., “A core gut microbiome in obese and lean twins,” Nature, vol. 457, no. 7228, pp. 480-484, 2008.
76. F. Backhed, H. Ding, T. Wang et al., “The gut microbiota as an environmental factor that regulates fat storage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 44, pp. 15718-15723, 2004.
77. C. De Filippo, D. Cavalieri, M. Di Paola et al., “Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14691-14696, 2010.
78. A. Schwiertz, D. Taras, K. Schäfer et al., “Microbiota and SCFA in lean and overweight healthy subjects,” Obesity, vol. 18, no. 1, pp. 190-195, 2010.
79. P. D. Cani and W. M. de Vos, “Next-generation beneficial microbes: the case of Akkermansia muciniphila,” Frontiers in Microbiology, vol. 8, p. 1765, 2017.
80. R. J. Perry, L. Peng, N. A. Barry et al., “Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome,” Nature, vol. 534, no. 7606, pp. 213-217, 2016.
81. J. P. Thaler, C. X. Yi, E. A. Schur et al., “Obesity is associated with hypothalamic injury in rodents and humans,” The Journal of Clinical Investigation, vol. 122, no. 1, pp. 153-162, 2012.
82. G. Frost, M. L. Sleeth, M. Sahuri-Arisoylu et al., “The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism,” Nature Communications, vol. 5, no. 1, p. 3611, 2014.
83. R. J. Seeley, A. P. Chambers, and D. A. Sandoval, “The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes,” Cell Metabolism, vol. 21, no. 3, pp. 369-378, 2015.
84. M. K. Hankir, F. Seyfried, C. A. Hintschich et al., “Gastric bypass surgery recruits a gut PPAR-α-striatal D1R pathway to reduce fat appetite in obese rats,” Cell Metabolism, vol. 25, no. 2, pp. 335-344, 2017.
85. K. Forslund, F. Hildebrand, T. Nielsen et al., “Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota,” Nature, vol. 528, no. 7581, pp. 262-266, 2015.
86. M. Roberfroid, “Prebiotics: the concept revisited,” The Journal of Nutrition, vol. 137, no. 3, pp. 830S-837S, 2007.
87. M. C. Mekkes, T. C. Weenen, R. J. Brummer, and E. Claassen, “The development of probiotic treatment in obesity: a review,” Beneficial Microbes, vol. 5, no. 1, pp. 19-28, 2014.
88. P. D. Cani and N. M. Delzenne, “The gut microbiome as therapeutic target,” Pharmacology & Therapeutics, vol. 130, no. 2, pp. 202-212, 2011.
89. L. Dethlefsen, S. Huse, M. L. Sogin, and D. A. Relman, “The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing,” PLoS Biology, vol. 6, no. 11, article e280, 2008.
90. E. Gough, H. Shaikh, and A. R. Manges, “Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection,” Clinical Infectious Diseases, vol. 53, no. 10, pp. 994-1002, 2011.
91. M. Rupnik, “Toward a true bacteriotherapy for clostridium difficile infection,” The New England Journal of Medicine, vol. 372, no. 16, pp. 1566-1568, 2015.
92. D. P. Bojanova and S. R. Bordenstein, “Fecal transplants: what is being transferred?,” PLoS Biology, vol. 14, no. 7, article e1002503, 2016.
93. E. van Nood, A. Vrieze, M. Nieuwdorp et al., “Duodenal infusion of donor feces for recurrent Clostridium difficile,” The New England Journal of Medicine, vol. 368, no. 5, pp. 407-415, 2013.
94. A. Vrieze, C. Out, S. Fuentes et al., “Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity,” Journal of Hepatology, vol. 60, no. 4, pp. 824-831, 2014.
95. D. Reijnders, G. H. Goossens, G. D. A. Hermes et al., “Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial,” Cell Metabolism, vol. 24, no. 1, pp. 63-74, 2016.
96. D. J. Morrison and T. Preston, “Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism,” Gut Microbes, vol. 7, no. 3, pp. 189-200, 2016.
97. R. DeFronzo, G. A. Fleming, K. Chen, and T. A. Bicsak, “Metformin-associated lactic acidosis: current perspectives on causes and risk,” Metabolism, vol. 65, no. 2, pp. 20-29, 2016.
98. J. C. Alves-Filho and E. M. Pålsson-McDermott, “Pyruvate kinase M2: a potential target for regulating inflammation,” Frontiers in Immunology, vol. 7, p. 145, 2016.